Published Online
on August 28, 2006

A more recent version of this article appeared on October 1, 2006

This Article Full Text (PDF) Data Supplements All Versions of this Article: 48/4/622    most recent 01.HYP.0000239816.13007.c9v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oliver, J. J. Articles by Webb, D. J. Search for Related Content PubMed PubMed Citation Articles by Oliver, J. J. Articles by Webb, D. J. Related Collections Cardiovascular Pharmacology Clinical Studies Endothelium/vascular type/nitric oxide Related Article

Submitted on April 4, 2006
Revised on April 24, 2006

Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension

James J. Oliver; Vanessa P. Melville; and David J. Webb^*

From the University of Edinburgh, United Kingdom.

^* To whom correspondence should be addressed. E-mail: d.j.webb{at}ed.ac.uk.

Abstract--There are no published controlled clinical trials of regular phosphodiesterase type 5 inhibitor therapy as a long-term treatment of hypertension. In a randomized, double-blind, 2-way crossover study, 25 otherwise untreated hypertensive subjects were administered 50 mg of sildenafil or matched placebo 3 times daily for 16 days, and the effects on ambulatory blood pressure (BP), clinic BP, arterial wave reflection, carotid-femoral pulse wave velocity, and brachial artery flow-mediated dilatation were assessed. Three subjects were withdrawn because of adverse effects, and the data from the remaining 22 subjects were analyzed. Sildenafil reduced ambulatory BP (mean [SE] change from baseline for average daytime BP: systolic -8 [2] mm Hg versus 2 [2] mm Hg with placebo, P<0.01; diastolic -6 [1] mm Hg versus 0 [1] mm Hg, P<0.01) and clinic BP (change from baseline to 1 hour after drug administration on day 16: systolic -5 [2] mm Hg versus 4 [2] mm Hg, P<0.01; diastolic -5 [1] mm Hg versus 2 [2] mm Hg, P<0.01). Compared with baseline, sildenafil, but not placebo, reduced arterial wave reflection both acutely and after chronic treatment, but the chronic change in arterial wave reflection was not statistically different from the chronic change with placebo. Sildenafil did not affect pulse wave velocity or flow-mediated dilatation. The main adverse effects of sildenafil, which were generally transient and rated as mild or moderate in severity, were dyspepsia, headache, and myalgia. In conclusion, regular sildenafil constitutes effective antihypertensive therapy. Further studies are warranted to evaluate the role of longer-acting phosphodiesterase type 5 inhibitors as antihypertensive agents in clinical practice.

Key words: phosphodiesterase 5 • sildenafil • hypertension • blood pressure • arterial stiffness

Related Article:

Phosphodiesterase 5 Inhibition to Treat Essential Hypertension: Is This the Beginning of the Story?

Stefano Taddei and Lorenzo Ghiadoni
Hypertension 2006 48: 546-548. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				R. Wolk, W. B. Smith, J. M. Neutel, J. Rubino, D. Xuan, J. Mancuso, J. Gilbert, and M. L. Pressler Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension Hypertension, June 1, 2009; 53(6): 1091 - 1097. [Abstract] [Full Text] [PDF]

				H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, and J. P. Spano Management of hypertension in angiogenesis inhibitor-treated patients Ann. Onc., May 1, 2009; 20(5): 807 - 815. [Abstract] [Full Text] [PDF]

				M. Guazzi Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure Circ Heart Fail, November 1, 2008; 1(4): 272 - 280. [Full Text] [PDF]

				F. Ahmed, B. A. Kemp, N. L. Howell, H. M. Siragy, and R. M. Carey Extracellular Renal Guanosine Cyclic 3'5'-Monophosphate Modulates Nitric Oxide and Pressure-Induced Natriuresis Hypertension, November 1, 2007; 50(5): 958 - 963. [Abstract] [Full Text] [PDF]

				N. G. Perez, M. R. Piaggio, I. L. Ennis, C. D. Garciarena, C. Morales, E. M. Escudero, O. H. Cingolani, G. Chiappe de Cingolani, X.-P. Yang, and H. E. Cingolani Phosphodiesterase 5A Inhibition Induces Na+/H+ Exchanger Blockade and Protection Against Myocardial Infarction Hypertension, May 1, 2007; 49(5): 1095 - 1103. [Abstract] [Full Text] [PDF]

				S. Taddei and L. Ghiadoni Phosphodiesterase 5 Inhibition to Treat Essential Hypertension: Is This the Beginning of the Story? Hypertension, October 1, 2006; 48(4): 546 - 548. [Full Text] [PDF]